The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)

Xia Jianzhen; Shi Tongxia; Cao Wenli

doi:doi:10.11648/j.sd.20210904.15

| Peer-Reviewed

The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)

Xia Jianzhen, Shi Tongxia, Cao Wenli

Published in Science Discovery (Volume 9, Issue 4)

Received: 12 April 2021 Published: 4 June 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective To observe the efficacy of Lianhua Qingwen Granule in the adjuvant treatment of community-acquired pneumonia (CAP). Methods From March 2018 to January 2020, adult patients with CAP who visited the internal medicine clinic of community health service center of Minzu University of China were divided by a random code list into two groups: the observation group (31cases), Lianhua Qingwen Granule orally combined with Levofloxacin intravenous drop, The control group (31 cases), Levofloxacin intravenous drop alonely. The cough symptom score, the cough visual simulation score (VAS), antipyretic time and X-ray chest shadow absorption were compared between the two groups to judge the curative effect. Measurement data were expressed as mean±standard deviation, and comparison used independent sample t test. Enumeration data were expressed as percentages, total effective rates were compared by χ² tests. Results There were no statistically significant differences in baseline data, such as age, score of cough symptom before treatment between the two groups. Compared with the control group, cough symptom score and VAS of observation group decreased significantly [(2.45±1.312) point vs (3.61±1.476) point, P=0.002], [(3.68±1.973) point vs (4.84±1.753) point, P=0.017], antipyretic time was decreased significantly [(3.00 ±1.4814) day VS (4.842±1.5728) day, P=0.001], effective rate was increased significantly (87.1% VS 64.5%, P=0.038). Compliance: the rate of hospital transfer without medical advice was decreased significantly (6.45% VS 29.03% P=0.046). Conclusion Lianhua Qingwen Granule combined with levofloxacin has good efficacy and compliance in the treatment of CAP, and community doctors can choose it.

Published in	Science Discovery (Volume 9, Issue 4)
DOI	10.11648/j.sd.20210904.15
Page(s)	155-159
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Community Acquired Pneumonia (CAP), Lianhua Qingwen Granule, Levofloxacin Injection, The Community Hospital, Compliance

References

[1]	中华医学会呼吸病学分会．中国成人社区获得性肺炎诊断与治疗指南(2016版)[J].中华结核和呼吸杂志，2016，39（4）：253-279．
[2]	Broulette J，Yu H，Pyenson B，et al. The Incidence Rate and Economic Burden of Community-Acquired Pneumonia in a Working-Age Population[J]. Am Health Drug Benefits，2013，6(8):494-503.
[3]	AKHTER S，RIZVI N，BHURA S，et al．Management of community acquired pneumonia by family physicians[J].Pak J Med Sci，2017，33（4）：783-787．
[4]	杨凯，朱云颖，肖婷婷，等．2019年美国IDSA/ATS成人社区获得性肺炎诊疗指南更新特点［Ｊ］．中华临床感染病杂志，2019,12(5):339-343.
[5]	陈宇红.我院成人社区获得性肺炎抗菌药物用药合理性分析[J].临床医药文献电子杂，2019，6（79）:10-11.
[6]	陈丽云，王银娣，黄汉. 连花清瘟胶囊抗流感病毒临床疗效观察[J].甘肃医药，2017.36（8）：666-667.
[7]	Metlay JP，Waterer GW，Long AC，et al. Diagnosis and treatment of adults with community-acquired pneumonia：an official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America[J].AmJ Respir Crit Care Med，2019,200（7）:e45-e67.
[8]	中华医学会呼吸病学分会哮喘学组．咳嗽的诊断与治疗指南(2015) [J].中华结核和呼吸杂志，2016，39(5)：323-354．
[9]	余业洲，赵红，邹立巍等．社区获得性肺炎治疗前后的影像学表现[J].中国医学影像学杂志，2019，27 （9）：674-676.
[10]	刘又宁，陈民钧，赵铁梅等．中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志，2006，29(1)：3-8．
[11]	陈亮，韩秀迪，李艳丽等. 具有吸入因素的社区获得性肺炎住院患者临床特征分析[J].医学研究生学报，2020，33（1）：54-61.
[12]	张菁，郁继诚，施耀国等.左氧氟沙星药代动力学/药效学研究[J].中华医学杂志，2005， 85（27）：1926-1932.
[13]	王晓文. 左氧氟沙星联合痰热清治疗老年支原体肺炎的临床分析[J].中华实验和临床感染病杂志:电子版，2015，9(3)：387-389.
[14]	Liu YF，Gao Y，Chen MF，et al. Etiological analysis and predictive diagnostic model building of community-acquired pneumonia in adult outpatients in Beijing，China[J].BMC Infect Dis，2013，13：309.
[15]	胡月,王宇，刘景院等.社区获得性肺炎病原学及耐药现状研究进展[J].中华实验和临床感染病杂志(电子版),2018,12(3).
[16]	Zhan Y，Yang Z，Chen R，et al. Respiratory virus is a real pathogen in immunocompetent community-acquired pneumonia: comparing to influenza like illness and volunteer controls[J].BMC Pulm Med，2014，14：144.
[17]	吕巍巍，贾鹏，张志贤等．磷酸奥司他韦治疗流行性感冒的临床疗效及不良反应分析[J].黑龙江医学，2018，42（8）：808，810.
[18]	丁新侃. 连花清瘟药物抗流感病毒的药理分析[J].临床合理用药，2012，5（10A）:32.
[19]	王守军.连花清瘟胶囊抗流感病毒药理机制研究[J].临床合理用药杂志，2019，12（05）：53-54.
[20]	Ding YW, Zeng LJ, Li RF，et al．The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function[J].BMC Complementary and Alternative Medicine 2017，17（1）:130.
[21]	丁月文，曾丽娟，李润峰等．连花清瘟颗粒抗呼吸道合胞病毒感染BALB／c小鼠的药效作用研究[J].广州中医药大学学报，2016，33（4）:540-544.
[22]	刘钊，石福忠，杨占秋．连花清瘟胶囊抗柯萨奇 B4 病毒作用的实验研究[J].中南民族大学学报(自然科学版)，2012，31(1):20 －24．
[23]	王妍，彭经纬，覃涛.连花清瘟颗粒对儿童肺炎支原体肺炎肺功能及炎性因子的影响[J].儿科药学杂志，2019，25（4）：35-37.
[24]	陈列强，陈文慧. 连花清瘟颗粒治疗小儿肺炎支原体肺炎[J].中国卫生标准管理，2020,11（11）：104-106.
[25]	董樑，夏敬文，龚益等. 连花清瘟胶囊治疗慢性阻塞性肺疾病急性加重期的临床疗效和作用机制[J].中成药，2014，36（5）：926-929.
[26]	陈波，姚扬伟，王海琴．连花清瘟颗粒联合莫西沙星片治疗老年社区获得性肺炎疗效观察[J].吉林医学，2013，34 （1）:79-80.
[27]	吕宏，欧阳张宁，王俊等．连花清瘟胶囊联合左氧氟沙星治疗肺炎的临床研究[J].现代药物与临床，2018，33(9):2294-2297.

Cite This Article

Plain Text BibTeX RIS

APA Style

Xia Jianzhen, Shi Tongxia, Cao Wenli. (2021). The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP). Science Discovery, 9(4), 155-159. https://doi.org/10.11648/j.sd.20210904.15

Copy | Download

ACS Style

Xia Jianzhen; Shi Tongxia; Cao Wenli. The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP). Sci. Discov. 2021, 9(4), 155-159. doi: 10.11648/j.sd.20210904.15

Copy | Download

AMA Style

Xia Jianzhen, Shi Tongxia, Cao Wenli. The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP). Sci Discov. 2021;9(4):155-159. doi: 10.11648/j.sd.20210904.15

Copy | Download

@article{10.11648/j.sd.20210904.15,
  author = {Xia Jianzhen and Shi Tongxia and Cao Wenli},
  title = {The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)},
  journal = {Science Discovery},
  volume = {9},
  number = {4},
  pages = {155-159},
  doi = {10.11648/j.sd.20210904.15},
  url = {https://doi.org/10.11648/j.sd.20210904.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20210904.15},
  abstract = {Objective To observe the efficacy of Lianhua Qingwen Granule in the adjuvant treatment of community-acquired pneumonia (CAP). Methods From March 2018 to January 2020, adult patients with CAP who visited the internal medicine clinic of community health service center of Minzu University of China were divided by a random code list into two groups: the observation group (31cases), Lianhua Qingwen Granule orally combined with Levofloxacin intravenous drop, The control group (31 cases), Levofloxacin intravenous drop alonely. The cough symptom score, the cough visual simulation score (VAS), antipyretic time and X-ray chest shadow absorption were compared between the two groups to judge the curative effect. Measurement data were expressed as mean±standard deviation, and comparison used independent sample t test. Enumeration data were expressed as percentages, total effective rates were compared by χ2 tests. Results There were no statistically significant differences in baseline data, such as age, score of cough symptom before treatment between the two groups. Compared with the control group, cough symptom score and VAS of observation group decreased significantly [(2.45±1.312) point vs (3.61±1.476) point, P=0.002], [(3.68±1.973) point vs (4.84±1.753) point, P=0.017], antipyretic time was decreased significantly [(3.00 ±1.4814) day VS (4.842±1.5728) day, P=0.001], effective rate was increased significantly (87.1% VS 64.5%, P=0.038). Compliance: the rate of hospital transfer without medical advice was decreased significantly (6.45% VS 29.03% P=0.046). Conclusion Lianhua Qingwen Granule combined with levofloxacin has good efficacy and compliance in the treatment of CAP, and community doctors can choose it.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)
AU  - Xia Jianzhen
AU  - Shi Tongxia
AU  - Cao Wenli
Y1  - 2021/06/04
PY  - 2021
N1  - https://doi.org/10.11648/j.sd.20210904.15
DO  - 10.11648/j.sd.20210904.15
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 155
EP  - 159
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20210904.15
AB  - Objective To observe the efficacy of Lianhua Qingwen Granule in the adjuvant treatment of community-acquired pneumonia (CAP). Methods From March 2018 to January 2020, adult patients with CAP who visited the internal medicine clinic of community health service center of Minzu University of China were divided by a random code list into two groups: the observation group (31cases), Lianhua Qingwen Granule orally combined with Levofloxacin intravenous drop, The control group (31 cases), Levofloxacin intravenous drop alonely. The cough symptom score, the cough visual simulation score (VAS), antipyretic time and X-ray chest shadow absorption were compared between the two groups to judge the curative effect. Measurement data were expressed as mean±standard deviation, and comparison used independent sample t test. Enumeration data were expressed as percentages, total effective rates were compared by χ2 tests. Results There were no statistically significant differences in baseline data, such as age, score of cough symptom before treatment between the two groups. Compared with the control group, cough symptom score and VAS of observation group decreased significantly [(2.45±1.312) point vs (3.61±1.476) point, P=0.002], [(3.68±1.973) point vs (4.84±1.753) point, P=0.017], antipyretic time was decreased significantly [(3.00 ±1.4814) day VS (4.842±1.5728) day, P=0.001], effective rate was increased significantly (87.1% VS 64.5%, P=0.038). Compliance: the rate of hospital transfer without medical advice was decreased significantly (6.45% VS 29.03% P=0.046). Conclusion Lianhua Qingwen Granule combined with levofloxacin has good efficacy and compliance in the treatment of CAP, and community doctors can choose it.
VL  - 9
IS  - 4
ER  -

Copy | Download

Author Information

Xia Jianzhen

Outpatient 1st Department, Community Hospital of Minzu University of China, Beijing, China
Shi Tongxia

Outpatient 1st Department, Community Hospital of Minzu University of China, Beijing, China
Cao Wenli

Infection 1st Department, Beijing Geriatric Hospital, Beijing, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Xia Jianzhen, Shi Tongxia, Cao Wenli. (2021). The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP). Science Discovery, 9(4), 155-159. https://doi.org/10.11648/j.sd.20210904.15

Copy | Download

ACS Style

Xia Jianzhen; Shi Tongxia; Cao Wenli. The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP). Sci. Discov. 2021, 9(4), 155-159. doi: 10.11648/j.sd.20210904.15

Copy | Download

AMA Style

Xia Jianzhen, Shi Tongxia, Cao Wenli. The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP). Sci Discov. 2021;9(4):155-159. doi: 10.11648/j.sd.20210904.15

Copy | Download

@article{10.11648/j.sd.20210904.15,
  author = {Xia Jianzhen and Shi Tongxia and Cao Wenli},
  title = {The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)},
  journal = {Science Discovery},
  volume = {9},
  number = {4},
  pages = {155-159},
  doi = {10.11648/j.sd.20210904.15},
  url = {https://doi.org/10.11648/j.sd.20210904.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20210904.15},
  abstract = {Objective To observe the efficacy of Lianhua Qingwen Granule in the adjuvant treatment of community-acquired pneumonia (CAP). Methods From March 2018 to January 2020, adult patients with CAP who visited the internal medicine clinic of community health service center of Minzu University of China were divided by a random code list into two groups: the observation group (31cases), Lianhua Qingwen Granule orally combined with Levofloxacin intravenous drop, The control group (31 cases), Levofloxacin intravenous drop alonely. The cough symptom score, the cough visual simulation score (VAS), antipyretic time and X-ray chest shadow absorption were compared between the two groups to judge the curative effect. Measurement data were expressed as mean±standard deviation, and comparison used independent sample t test. Enumeration data were expressed as percentages, total effective rates were compared by χ2 tests. Results There were no statistically significant differences in baseline data, such as age, score of cough symptom before treatment between the two groups. Compared with the control group, cough symptom score and VAS of observation group decreased significantly [(2.45±1.312) point vs (3.61±1.476) point, P=0.002], [(3.68±1.973) point vs (4.84±1.753) point, P=0.017], antipyretic time was decreased significantly [(3.00 ±1.4814) day VS (4.842±1.5728) day, P=0.001], effective rate was increased significantly (87.1% VS 64.5%, P=0.038). Compliance: the rate of hospital transfer without medical advice was decreased significantly (6.45% VS 29.03% P=0.046). Conclusion Lianhua Qingwen Granule combined with levofloxacin has good efficacy and compliance in the treatment of CAP, and community doctors can choose it.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)
AU  - Xia Jianzhen
AU  - Shi Tongxia
AU  - Cao Wenli
Y1  - 2021/06/04
PY  - 2021
N1  - https://doi.org/10.11648/j.sd.20210904.15
DO  - 10.11648/j.sd.20210904.15
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 155
EP  - 159
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20210904.15
AB  - Objective To observe the efficacy of Lianhua Qingwen Granule in the adjuvant treatment of community-acquired pneumonia (CAP). Methods From March 2018 to January 2020, adult patients with CAP who visited the internal medicine clinic of community health service center of Minzu University of China were divided by a random code list into two groups: the observation group (31cases), Lianhua Qingwen Granule orally combined with Levofloxacin intravenous drop, The control group (31 cases), Levofloxacin intravenous drop alonely. The cough symptom score, the cough visual simulation score (VAS), antipyretic time and X-ray chest shadow absorption were compared between the two groups to judge the curative effect. Measurement data were expressed as mean±standard deviation, and comparison used independent sample t test. Enumeration data were expressed as percentages, total effective rates were compared by χ2 tests. Results There were no statistically significant differences in baseline data, such as age, score of cough symptom before treatment between the two groups. Compared with the control group, cough symptom score and VAS of observation group decreased significantly [(2.45±1.312) point vs (3.61±1.476) point, P=0.002], [(3.68±1.973) point vs (4.84±1.753) point, P=0.017], antipyretic time was decreased significantly [(3.00 ±1.4814) day VS (4.842±1.5728) day, P=0.001], effective rate was increased significantly (87.1% VS 64.5%, P=0.038). Compliance: the rate of hospital transfer without medical advice was decreased significantly (6.45% VS 29.03% P=0.046). Conclusion Lianhua Qingwen Granule combined with levofloxacin has good efficacy and compliance in the treatment of CAP, and community doctors can choose it.
VL  - 9
IS  - 4
ER  -

Copy | Download